NLA Recommendations & Statements

On June 3, 2015, the anticipated final results of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) was published online in the New England Journal of Medicine (NEJM 2015;372:2387-97).



Publish Date:
June 5, 2015 - 12:00pm
Last Updated: May, 2017

The National Lipid Association (NLA) recently convened an Expert Panel on Statin Safety to examine various aspects of statin therapy and to determine its safety, patient tolerance and effectiveness.



Publish Date:
May 20, 2014 - 12:00pm
Last Updated: Jan, 2017

The NLA held a consensus conference in January 2011 to bring together experts on inflammatory markers and advanced lipoprotein testing for the generation of an NLA statement of clinical guidance regarding the utility of various biomarkers. The panel reviewed apolipoprotein B (Apo B), C-reactive protein (CRP), high-density lipoprotein (HDL) subfractions, lipoprotein-associated phospholipase A2 (Lp-PLA2), low-density lipoprotein (LDL) subfractions, low-density lipoprotein particle number/concentration (LDL-P), and lipoprotein (a) (Lp(a)).



Publish Date:
October 4, 2011 - 12:00pm
Last Updated: Oct, 2020

Click here to view the manuscript. 

Adapted from an article in the Journal of Clinical Lipidology (JCL) titled, The Importance of Non-HDL Cholesterol Reporting in Lipid Management1



Publish Date:
September 8, 2011 - 12:00am
Last Updated: Oct, 2020

In connection with the Familial Hypercholesterolemia ("FH") initiative of the Foundation of the National Lipid Association, the NLA held a consensus conference in January 2011 to bring together experts on FH for the generation of an NLA statement of clinical guidance regarding the diagnosis and treatment FH. Click here to view the manuscript, published in the May 2011 edition of the Journal of Clinical Lipidology.



Publish Date:
June 1, 2011 - 12:00am
Last Updated: Aug, 2020